Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2

Zhao, 2003, Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits, Clin Chim Acta, 336, 103, 10.1016/S0009-8981(03)00335-8 Francis, 2003, PPAR agonists in the treatment of atherosclerosis, Curr Opin Pharmacol, 3, 186, 10.1016/S1471-4892(03)00014-6 Grip, 2002, Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes, Inflamm Res, 51, 58, 10.1007/BF02684000 Atar, 2006, Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2, Am J Physiol Heart Circ Physiol, 290, H1960, 10.1152/ajpheart.01137.2005 Birnbaum, 2005, Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury, Cardiovasc Res, 65, 345, 10.1016/j.cardiores.2004.10.018 Ye, 2006, Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions, Am J Physiol Heart Circ Physiol, 291, H1158, 10.1152/ajpheart.00096.2006 Shibata, 2002, 15-deoxy-delta 12 14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes, J Biol Chem, 277, 10459, 10.1074/jbc.M110314200 Sasaguri, 2004, Prostaglandin J2 family and the cardiovascular system, Curr Vasc Pharmacol, 2, 103, 10.2174/1570161043476384 Liu, 2004, Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells, Circulation, 110, 1128, 10.1161/01.CIR.0000139850.08365.EC Lee, 2003, Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors, Endocrinology, 144, 2201, 10.1210/en.2003-0288 Birnbaum, 2006, Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat, Circulation, 114, 929, 10.1161/CIRCULATIONAHA.106.629907 Scher, 2005, 15d-PGJ2: the anti-inflammatory prostaglandin?, Clin Immunol, 114, 100, 10.1016/j.clim.2004.09.008 Zhang, 2004, Role of PPARgamma in macrophage biology and atherosclerosis, Trends Endocrinol Metab, 15, 500, 10.1016/j.tem.2004.10.006 Freeman, 2001, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation, 103, 357, 10.1161/01.CIR.103.3.357 Huptas, 2006, Effect of atorvastatin (10mg/day) on glucose metabolism in patients with the metabolic syndrome, Am J Cardiol, 98, 66, 10.1016/j.amjcard.2006.01.055 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22. Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335–41. Sabatine, 2004, High dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 Substudy [Abstract], Circulation, 110 Ohmura, 2005, Acute onset and worsening of diabetes concurrent with administration of statins, Endocr J, 52, 369, 10.1507/endocrj.52.369 Nakata, 2006, Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control, Diabetologia, 49, 1881, 10.1007/s00125-006-0269-5 Ichida, 2006, Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes, Pharmacology, 76, 34, 10.1159/000088948 Paolisso, 2000, Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients, Atherosclerosis, 150, 121, 10.1016/S0021-9150(99)00352-4 Yada, 1999, Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells, Br J Pharmacol, 126, 1205, 10.1038/sj.bjp.0702397 Kanda, 2003, Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin, Biol Pharm Bull, 26, 1681, 10.1248/bpb.26.1681 Mensah, 2005, Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?, J Am Coll Cardiol, 45, 1287, 10.1016/j.jacc.2005.01.021 Wong, 2006, Atorvastatin induces insulin sensitization in Zucker lean and fatty rats, Atherosclerosis, 184, 348, 10.1016/j.atherosclerosis.2005.05.009 Jiang, 2005, Modulation of insulin signalling by insulin sensitizers, Biochem Soc Trans, 33, 358, 10.1042/BST0330358